You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 [see all tables in this series...]

Part (iv) Percentage amongst new clients with hypnotics and sedatives as primary drug

Country		Inject	Smoke/inhale	Eat/drink	Sniff	Others	Base (known status)	Status unknown
Bulgaria		0.0	0.0	100.0	0.0	0.0	1	0
Czech Republic		0.0	0.0	100.0	0.0	0.0	6	0
Denmark		0.0	0.0	100.0	0.0	0.0	17	4
Germany		3.1	2.8	88.4	1.2	4.5	509	295
Ireland		0.0	0.0	100.0	0.0	0.0	33	2
Greece		0.0	0.0	100.0	0.0	0.0	17	1
Spain	(1)	0.0	1.4	98.1	0.5	0.0	431	5
France		0.0	0.0	91.7	5.6	2.8	36	0
Italy		0.0	0.0	74.4	0.0	25.6	242	0
Cyprus		0.0	0.0	100.0	0.0	0.0	2	0
Latvia		0.0	0.0	100.0	0.0	0.0	33	2
Lithuania		0.0	0.0	100.0	0.0	0.0	8	0
Hungary		3.6	0.8	95.6	0.0	0.0	248	0
Malta		0.0	0.0	100.0	0.0	0.0	2	1
Netherlands	(2)	0.0	2.8	95.4	1.9	0.0	108	12
Slovakia		0.0	0.0	100.0	0.0	0.0	4	0
Finland		3.6	3.6	92.9	0.0	0.0	28	0
Sweden		0.0	0.0	100.0	0.0	0.0	119	2
United Kingdom	(3)	0.6	0.8	90.3	0.4	7.9	1118	81
Total		1.1	1.2	91.3	0.6	5.9	2962	405

Notes:

Only countries where there are clients reported with hypnotics and sedatives as primary drug are shown.

(1) Data refer to 2004.

(2) Data refer to outpatient treatment centres and low-threshold agencies.

(3) Data refer to collection period between 01.04.2004 and 31.03.2005.

See also 'Table TDI-110' for cocaine CIH and crack route of administration distribution, and 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports - TDI - outpatient treatment centres.